Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy

AIDS

Volumn 16, Issue 8, 2002, Pages 1131-1138

  Baxter, John D ^a,e   Merigan, Thomas C ^b   Wentworth, Deborah N ^c   Neaton, James D ^c   Hoover, Marie L ^d   Hoetelmans, Richard M W ^e   Piscitelli, Stephen C ^e   Verbiest, Werner H A ^e   Mayers, Douglas L ^f,g  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d Advanced BioMedical Laboratories   (United States)

^e VIRCO ^*  (United States)

^f HENRY FORD HOSPITAL   (United States)

^g BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Antiretroviral therapy; HIV drug resistance resistance mutations; Pharmacokinetics drug interactions; Viral load

Indexed keywords

ANTIVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IC 50; MAJOR CLINICAL STUDY; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; UNITED STATES; VIRUS LOAD;

ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; PATIENT COMPLIANCE; PHENOTYPE; SALVAGE THERAPY; VIRAL LOAD;

EID: 0037165931     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200205240-00006     Document Type: Article

References (27)

1. Drug resistance genotyping in HIV-1 therapy: The VIRADAPT randomized controlled trial
2. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt study: Week 48 follow-up
3. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
4. Current knowledge and future prospects for the used of HIV protease inhibitors
5. Ritonavir clinical pharmacokinetics and interactions with others anti-HIV agents
6. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study
7. A 6-base pair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors
8. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type-1 isolates from patients treated with antiretroviral drugs
9. Synergism of resistance testing and therapeutic drug monitoring in the optimization of HIV-1 therapy
10. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
11. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)
12. Indinavir pharmacokinetics and relationships between exposure and antiviral effect
13. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1 infected patients on indinavir-containing triple therapy
14. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1
15. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
16. Response to ritonavir (RTV) intensification in indinavir (IDV) recipients is highly correlated with inhibitory quotient
17. Evaluation of the inhibitory quotient as a pharmacodynamic predictor of the virologic response to protease inhibitor therapy
18. A novel approach to integrate pharmacologic and virologic characteristics: An in vivo potency index for antiretroviral agents
19. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients
20. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
21. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir and saquinavir
22. Pharmacologic characteristics of efavirenz and nelfinavir associated with virologic response in HIV-infected children
23. Therapeutic drug monitoring of indinavir in treatment naïve patients improves therapeutic outcome after 1 year: Results from ATHENA
24. Therapeutic drug monitoring of nelfinavir 1250 bid in treatment naïve patients improves therapeutic outcome after I year: Results from ATHENA
25. Usefulness of protease inhibitor therapeutic drug monitoring? PharmAdapt: A prospective multicentric randomized controlled trial: 12 Week results
26. Utility of HIV genotyping and clinical expert advice: The Havanna Trial
27. Phenotypic resistance testing significantly improves response to therapy: Final analysis of a randomized trial (VIRA3001)